痰热清注射液联合布地奈德福莫特罗对稳定期COPD患者炎症及免疫功能的影响

付海卫; 李小波; 孔一名; 郭微微; 杨再兴; 戴元荣

doi:10.16766/j.cnki.issn.1674-4152.000005

痰热清注射液联合布地奈德福莫特罗对稳定期COPD患者炎症及免疫功能的影响

doi: 10.16766/j.cnki.issn.1674-4152.000005

温州医科大学附属黄岩医院呼吸内科, 浙江温州 318020

基金项目:

国家自然科学基金(81671594)

详细信息

通讯作者:
戴元荣,E-mail:daiyr@126.com

中图分类号: R563;R977.1
计量
- 文章访问数: 148
- HTML全文浏览量: 21
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-26

Effects of Tanreqing injection combined bridgestone on inflammation and immune function of patients with stable COPD

Respiratory Medicine Department of Huangyan Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 318020, China

摘要

摘要: 目的探讨痰热清注射液联合布地奈德福莫特罗对稳定期慢性阻塞性肺疾病(COPD)患者肺功能、动脉血气、炎症及免疫功能的影响。方法选取2016年1月-2017年1月温州医科大学附属黄岩医院就诊的稳定期COPD患者156例,将其按随机数字法分为2组,每组78例。对照组给予布地奈德福莫特罗,观察组在对照组基础上加用痰热清注射液。治疗后,比较2组肺功能(FEV₁、FEV₁%、FEV₁/FEVC)及动脉血气(PaO₂、PaCO₂)、炎症因子(TNF-α、IL-8、ICAM-1)及免疫功能(CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺)的变化。结果治疗后,2组FEV₁、FEV₁%、FEV₁/FVC均明显升高(P<0.05),且观察组高于对照组(P<0.05)。治疗后,2组PaO₂均升高(均P<0.05),且观察组明显高于对照组(P<0.05),2组PaCO₂均降低(均P<0.05),且观察组明显低于对照组(P<0.05)。治疗后,2组TNF-α、IL-8、ICAM-1均明显降低(均P<0.05),且观察组低于对照组(P<0.05)。治疗后,2组CD3⁺、CD4⁺、CD4⁺/CD8⁺均显著升高(均P<0.05),且观察组高于对照组(P<0.05)。结论痰热清注射液联合布地奈德福莫特罗能够降低稳定期COPD患者炎症反应,提高患者免疫功能,有效改善患者的肺功能及动脉血气水平。
- 慢性阻塞性肺疾病 /
- 痰热清注射液 /
- 布地奈德福莫特罗
Abstract: Objective To investigate the effect of Tanreqing injection combined budesonide dermoterol on inflammatory factors, immune function, pulmonary function and arterial blood gas of patients with stable COPD. Methods One hundred and fifty-six patients with stable COPD were randomly divided into two groups, 78 cases in each group. The control group was given budesonide/formoterol, and the observation group was added Tanreqing injection based control group.The inflammatory factors (TNF-α, IL-8 and ICAM-1), immune function (CD3⁺, CD4⁺, CD8⁺and CD4⁺/CD8⁺), pulmonary function (FEV₁, FEV₁% and FEV₁/FEVC), arterial blood gas (PaO₂ and PaCO₂) of two groups were compared. Results After treatment, TNF-α, IL-8 and ICAM-1 levels of two groups were significantly reduced (P<0.05), and observation group was lower than the control group (P<0.05). After treatment, CD3⁺, CD4⁺and CD4⁺/CD8⁺levels of two groups were significantly increased (P<0.05), and observation group was higher than the control group (P<0.05). After treatment, FEV₁, FEV₁% and FEV₁/FVC levels of two groups were significantly increased (P<0.05), and observation group was higher than the control group (P<0.05). After treatment, PaO₂ levels of two groups were significantly increased (P<0.05), and observation group was higher than the control group (P<0.05). After treatment, PaCO₂ levels of two groups were significantly reduced (P<0.05), and observation group was lower than the control group (P<0.05). Conclusion Tanreqing injection combined budesonide dermotam could reduce the inflammatory response, improve the immune function, and improve the lung function and arterial blood gas of patients with COPD.
- COPD /
- Tanreqing injection /
- Budesonide fumoterol